Earnings History Data for Immunovant (IMVT) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Immunovant

Immunovant Inc. is a clinical-stage biopharmaceutical company focused on autoimmune diseases. The company's product candidate consists of IMVT-1401 which is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor which is in clinical stage. Immunovant Inc. is based in New York, United States.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
07-11-2024	PM		IMVT	Immunovant	4,438	-0.74	-0.61	0.00	Immunovant GAAP EPS of -$0.74 [11/7/2024 9:27 AM]	30.00	-1.42 (-4.50%)	30.52	-0.90 (-2.86%)	24.67 - 45.58	609,811	630,000	2,314
Immunovant GAAP EPS of -$0.74 [11/7/2024 9:27 AM] Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 [2024-11-07 06:30AM]
06-08-2024	AH		IMVT	Immunovant	4,074	-0.60	-0.52	0.00	Immunovant GAAP EPS of -$0.60 misses by $0.07 [8/6/2024 5:24 PM]	27.01	-0.84 (-3.02%)	27.85	0.0 (0.00%)	18.82 - 45.58	1,092,251	1,000,000	15,381
Immunovant GAAP EPS of -$0.60 misses by $0.07 [8/6/2024 5:24 PM]
29-05-2024	AH		IMVT	Immunovant	4,206	-0.52	-0.43	0.00	Immunovant GAAP EPS of -$0.52 misses by $0.08 [5/29/2024 5:05 PM]	26.25	-3.32 (-11.23%)	27.50	-2.07 (-7.00%)	18.16 - 45.58	5,266,902	930,000	28,017
Immunovant GAAP EPS of -$0.52 misses by $0.08 [5/29/2024 5:05 PM]
09-11-2023	PM		IMVT	Immunovant	4,521	-0.45	-0.46	0.00	Immunovant GAAP EPS of -$0.45 beats by $0.03 [11/9/2023 8:01 AM]	31.33	-2.06 (-6.17%)	0.0	0.0 (0.00%)	11.54 - 44.19	1,359,375	1,190,000	0
Immunovant GAAP EPS of -$0.45 beats by $0.03 [11/9/2023 8:01 AM] Immunovant files automatic mixed shelf [11/9/2023 1:58 PM]
10-08-2023	PM		IMVT	Immunovant	2,842	-0.47	-0.44	0.00	Immunovant GAAP EPS of -$0.57 misses by $0.13 [8/10/2023 10:42 AM]	22.31	1.39 (6.64%)	0.0	0.0 (0.00%)	4.26 - 25.13	848,830	810,000	0
Immunovant GAAP EPS of -$0.57 misses by $0.13 [8/10/2023 10:42 AM]
22-05-2023	PM		IMVT	Immunovant	2,765	-0.46	-0.48	0.00		23.80	2.59 (12.21%)	0.0	0.0 (0.00%)	3.14 - 24.18	2,713,184	910,000	0
Immunovant up 12% following autoimmune candidate IND clearance [5/22/2023 3:30 PM]
08-06-2022	PM		IMVT	Immunovant, Inc.	370.61	-0.41	-0.38	-0.29	Immunovant GAAP EPS of -$0.41 misses by $0.05 [6/8/2022 7:32 AM]	3.92	-0.35 (-8.20%)	4.48	0.21 (4.92%)	3.55 - 11.61	189,312	320,000	375
Immunovant GAAP EPS of -$0.41 misses by $0.05 [6/8/2022 7:32 AM] Immunovant to begin pivotal trials for batoclimab for thyroid eye disease in 2H 2022 [6/8/2022 9:30 AM] Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022 [Jun-06-22 04:47PM] Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 [Jun-08-22 07:00AM] Immunovant To Start Pivotal Batoclimab Trials In Thyroid Eye Disease Later This Year [Jun-08-22 09:27AM]
05-11-2021	PM		IMVT	Immunovant	1,019	-0.35	-0.26	0.00	Immunovant EPS misses by $0.08 [11/5/2021 9:06 AM]	8.55	-0.17 (-1.95%)	8.45	-0.27 (-3.10%)	6.68 - 53.75	495,761	460,000	3,132
Immunovant EPS misses by $0.08 [11/5/2021 9:06 AM] Immunovant Reports Financial Results for the Quarter Ended September 30, 2021 [Nov-05-21 07:30AM]
09-08-2021	PM	7:30 AM ET (Aug 9)	IMVT	Immunovant, Inc.	761.00	-0.31	-0.30	0.00	Immunovant EPS in-line [8/9/2021 6:43 AM]	7.77	0.02 (0.26%)	7.70	-0.05 (-0.65%)	6.68 - 53.75	932,227	2,840,000	6,107
Immunovant EPS in-line [8/9/2021 6:43 AM] Immunovant Reports Financial Results for the Quarter Ended June 30, 2021 [Aug-09-21 06:30AM] Immunovant to Report Financial Results for Quarter Ended June 30, 2021 [Aug-06-21 04:22PM]
01-06-2021	PM		IMVT	Immunovant, Inc.	1,485	-0.29	-0.33	0.00	Immunovant EPS beats by $0.04 [6/1/2021 8:59 AM]	9.63	-5.53 (-36.48%)	11.38	-3.78 (-24.93%)	9.22 - 53.75	15,693,076	500,000	238,027
Immunovant tumbles as chief medical officer departs [6/1/2021 9:37 AM] Immunovant EPS beats by $0.04 [6/1/2021 8:59 AM] Immunovant plans to resume clinical development of IMVT-1401 [6/1/2021 8:25 AM] AMBA, ZM, IRTC and HOLX among after-hours movers [6/1/2021 5:40 PM] Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter and Fiscal Year Ended March 31, 2021 [Jun-01-21 07:31AM]
16-02-2021	PM		IMVT	Immunovant, Inc.	2,176	-0.32	-0.26	0.00	Immunovant reports Q3 results [2/16/2021 8:06 AM]	16.12	-6.09 (-27.42%)	22.50	0.29 (1.31%)	8.34 - 53.75	6,480,754	2,747,923	14,551
Immunovant reports Q3 results [2/16/2021 8:06 AM] Immunovant Reports Financial Results for the Quarter and Nine Months Ended December 31, 2020 [Feb-16-21 08:00AM] SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immunovant, Inc. - IMVT [Feb-15-21 09:37PM] SHAREHOLDER INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Immunovant, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm [Feb-15-21 10:41AM]
29-06-2020	PM		IMVT	Immunovant, Inc.	2,050	-0.38	-0.53	0.00	Immunovant EPS beats by $0.20 [6/29/2020 7:50 AM]	25.52	-1.85 (-6.76%)	27.81	0.44 (1.61%)	8.34 - 29.96	107,235	1,077,860	241,328